HMC is an independent investment firm focused on fundamentally-based private and public market strategies. We seek investments forecasted to yield mid- to high-teen returns. Our mission is to provide strong and consistent returns to help our clients meet their investment objectives and preserve initial investment capital. We are opportunistic investors who invest alongside our clients on equal terms and conditions.
January 13, 2017 - HGP – MaxCyte Announces Strategic Immuno-Oncology Collaboration to Advance New Generation of CAR-based Cell Therapies
January 13, 2017 - HGP – MaxCyte, NIH NIAID Study Published in Science Translational Medicine Demonstrates CRISPR-Cas9 Repair of X-linked Chronic Granulomatous Disease (CGD) Gene
HMC has offices in eleven locations across the United States and Europe. Harbert's committed capital and Regulatory Assets Under Management have grown from $1.5 billion in 2002 to approximately $4.5 billion as of December 31, 2016.